natgillin/translations-raw huggingface dataset:
Convulsions have occurred rarely with levodopa/carbidopa; however a causal relationship to levodopa/carbidopa therapy has not been established.
Redko so se ob levodopi/karbodopi pojavile konvulzije, vendar pa vzročna zveza z levodopo/karbidopo ni bila potrjena.
- Levodopa/Carbidopa/Entacapone Orion is not recommended for the treatment of drug-induced extrapyramidal reactions.
- Zdravilo Levodopa/Carbidopa/Entacapone Orion se ne priporoča za zdravljenje ekstrapiramidnih reakcij, ki jih povzročajo zdravila.
Total clearance for levodopa is in the range of 0.55-1.38 l/kg/h and for entacapone is in the range of 0.70 l/kg/h.
Celokupen očistek levodope se giblje v razponu med 0,55-1,38 l/kg/h, entakapona pa okrog 0,70 l/kg/h.
Caution should be exercised when the following active substances are administered concomitantly with levodopa therapy.
Previdnost je potrebna, kadar se sočasno z levodopo uporabljajo naslednje učinkovine:
Carbidopa is absorbed and eliminated slightly slower compared with levodopa.
V primerjavi s levodopo se karbidopa absorbira in izloča nekoliko počasneje.
These include: - dopamine antagonists used to treat mental disorders, nausea and vomiting - phenytoin, used to prevent convulsions - papaverine used to relax the muscles.
Taka zdravila so: - dopaminski antagonisti, ki se uporabljajo za zdravljenje duševnih motenj, slabosti in bruhanja - fenitoin, ki se uporablja za preprečevanje krčev - papaverin, ki se uporablja za mišično relaksacijo
Both levodopa and combinations of carbidopa and levodopa have caused visceral and skeletal malformations in rabbits.
Tako levodopa kot tudi kombinacija karbidope in levodope so povzročile motnje v razvoju visceralnih organov in skeleta pri zajcih.
When given separately without the two other active substances, the bioavailability for levodopa is 15-33%, for carbidopa 40-70% and for entacapone 35% after a 200 mg oral dose.
Pri samostojni aplikaciji peroralnega odmerka 200 mg brez ostalih dveh učinkovin je bila biološka uporabnost levodope 1533 %, karbidope 40-70 %, entakapona pa 35 %.
Tabulated list of adverse reactions
b. Tabelarični pregled neželenih učinkov
Red iron oxide (E172)
rdeči železov oksid (E172) saharoza titanov dioksid (E171) rumeni železov oksid (E172)
75 mg/18.75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31.25 mg/200 mg or
75 mg/18,75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31,25 mg/200 mg ali
There are no significant differences in the AUC of carbidopa or entacapone between younger (45-64 years) and elderly (65-75 years).
Med mlajšimi (45-64 let) in starejšimi (65-75 let) ni značilne razlike v AUC vrednostih karbidope ali entakapona.
Parkinsonism aggravated (e.g. bradykinesia)*, tremor, on and off phenomenon, dystonia, mental impairment (e.g. memory impairment, dementia), somnolence, dizziness*, headache
poslabšanje parkinsonizma (npr. bradikinezija)*,tremor, fenomen vklop/izklop, distonija, duševna motnja (npr. motnja pomnjenja, demenca), somnolenca, omotica*, glavobol
Levodopa, carbidopa and entacapone together may cause dizziness and symptomatic orthostatism.
Levodopa, karbidopa in entakapon skupaj lahko povzročajo vrtoglavico in simptomatsko ortostatsko hipotenzijo.
It may therefore be necessary, particularly in patients with dyskinesia, to reduce levodopa dose by 10-30% within the first days to first weeks after initiating Levodopa/Carbidopa/Entacapone Orion treatment.
Zato bo morda potrebno v prvih dneh oziroma prvih tednih po uvedbi zdravljenja z zdravilom Levodopa/Carbidopa/Entacapone Orion, zlasti pri bolnikih z diskinezijo zmanjšati odmerek levodope za 10-30 %.
Antihypertensives: Symptomatic postural hypotension may occur when levodopa is added to the treatment of patients already receiving antihypertensives.
Antihipertenzivi: Kadar se levodopa uvede v zdravljenje bolnikov, ki že prejemajo antihipertenzive, lahko pride do simptomatske posturalne hipotenzije.
If other levodopa products are used concomitantly with a Levodopa/Carbidopa/Entacapone Orion tablet, the maximum dose recommendations should be followed.
Če se sočasno s tabletami zdravila Levodopa/Carbidopa/Entacapone Orion uporabljajo druga zdravila z levodopo, je treba upoštevati priporočila o največjem dovoljenem odmerjanju.
When less levodopa is required, the total daily dose of Levodopa/Carbidopa/Entacapone Orion should be reduced either by decreasing the frequency of administration by extending the time between doses, or by decreasing the strength of Levodopa/Carbidopa/Entacapone Orion at an administration.
Kadar je potreben manjši odmerek levodope, se skupni dnevni odmerek zdravila Levodopa/Carbidopa/Entacapone Orion zmanjša bodisi z manj pogostimi odmerki, tako da se podaljša interval med posameznimi odmerki, ali pa z uporabo zdravila Levodopa/Carbidopa/Entacapone Orion manjše jakosti.
Fertility studies in animals have not been conducted with the combination of entacapone, levodopa and carbidopa.
Študij na živalih o vplivu kombinacije entakapona, karbidope in levodope na plodnost niso opravili.
When considered necessary, the replacement of Levodopa/Carbidopa/Entacapone Orion with levodopa and DDC inhibitor without entacapone or other dopaminergic treatment should proceed slowly and an increase in levodopa dose may be necessary.
Kadar je to potrebno, naj se zdravilo Levodopa/Carbidopa/Entacapone Orion nadomesti z levodopo in zaviralcem DDK brez entakapona postopoma, morda pa bo tudi potrebno povečati odmerek levodope.
Consult your doctor if during the treatment with Levodopa/Carbidopa/Entacapone Orion you: - notice that your muscles get very rigid or jerk violently, or if you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure.
Posvetujte se z zdravnikom, če (se) med zdravljenjem z zdravilom Levodopa/Carbidopa/Entacapone Orion: - opazite, da postajajo mišice zelo toge ali silovito trzajo, če se začnete tresti, postanete vznemirjeni, zmedeni, dobite zvišano telesno temperaturo, zvišan srčni utrip ali se pojavi veliko nihanje krvnega tlaka.
Some patients experience severe abnormal involuntary movements (dyskinesias), mood swings or other side effects after taking large doses of Levodopa/Carbidopa/Entacapone Orion.
Pri nekaterih bolnikih se pojavijo hudi nenormalni nehoteni gibi (diskinezija), nihanje razpoloženja ali drugi neželeni učinki, ki se pojavijo po jemanju visokih odmerkov zdravila Levodopa/Carbidopa/Entacapone Orion.
Pyridoxine, however, is not effective in reversing the actions of Levodopa/Carbidopa/Entacapone Orion.
Vendar pa piridoksin ni učinkovit kot protisredstvo za delovanje zdravila Levodopa/Carbidopa/Entacapone Orion.
For adults and elderly: - Your doctor will tell you exactly how many tablets of Levodopa/Carbidopa/Entacapone Orion to take each day.
Za odrasle in starejše: - Vaš zdravnik vam bo povedal, koliko tablet zdravila Levodopa/Carbidopa/Entacapone Orion morate vzeti vsak dan. - Tableta ni namenjena za deljenje ali drobljenje na manjše koščke.
Serious events of gastrointestinal haemorrhage (uncommon) and angioedema (rare) have been identified from the clinical trials with Levodopa/Carbidopa/Entacapone Orion or entacapone combined with levodopa/DDC inhibitor.
Huda neželena učinka, gastrointestinalne krvavitve (občasno) in angioedem (redko), so opredelili v kliničnih preskušanjih z zdravilom Levodopa/Carbidopa/Entacapone Orion ali entakapon v kombinaciji z levodopo/zaviralcem dekarboksilaze.
Dopamine Dysregulation Syndrome (DDS) is an addictive disorder seen in some patients treated with carbidopa/levodopa.
Sindrom motene regulacije dopamina (DDS) je odvistnostna motnja, opažena pri nekaterih bolnikih, zdravljenih s karbidopo/levodopo.
However, no interaction with carbidopa has been observed with the recommended treatment schedule (200 mg of entacapone up to 10 times daily).
Vendar pa ob priporočenem terapevtskem režimu (200 mg etakapona do 10-krat dnevno) niso opazili nobenih interakcij s karbidopo.
If you during the treatment with Levodopa/Carbidopa/Entacapone Orion experience the following symptoms, contact your doctor immediately: - Your muscles get very rigid or jerk violently, you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure.
Če v času zdravljenja z zdravilom Levodopa/Carbidopa/Entacapone Orion opazite naslednje simptome, o tem nemudoma obvestite zdravnika: - Mišice postanejo zelo toge ali silovito trzajo, začnete se tresti, ste vznemirjeni, zmedeni, dobite zvišano telesno temperaturo, zvišan srčni utrip ali se pojavi veliko nihanje krvnega tlaka.
Usually Levodopa/Carbidopa/Entacapone Orion is to be used in patients who are currently treated with corresponding doses of standard release levodopa/DDC inhibitor and entacapone.
Običajno naj bi se zdravilo Levodopa/Carbidopa/Entacapone Orion uporabljalo pri bolnikih, ki trenutno prejemajo ustrezne odmerke zaviralcev DDK s standardnim sproščanjem levodope in entakapona.
No particular studies on the pharmacokinetics of carbidopa and levodopa in patients with hepatic impairment are reported, however, it is advised that Levodopa/Carbidopa/Entacapone Orion should be administered cautiously to patients with mild or moderate hepatic impairment.
Ni poročil o posebnih raziskavah farmakokinetike karbidope in levodope pri bolnikih z okvaro jeter, vendar pa se priporoča previdnost pri dajanju zdravila Levodopa/Carbidopa/Entacapone Orion bolnikom z blago do zmerno okvaro jeter.
Pack sizes of 50/12.5/200 mg, 100/25/200 mg and 150/37.5/200 mg: 10, 30, 100, 130, 175 and 250 tablets.
Velikosti pakiranj za 50/12,5/200 mg, 100/25/200 mg, 150/37,5/200 mg: 10, 30, 100, 130, 175 in 250 tablet.
The possibility that the patient has taken other active substances in addition to Levodopa/Carbidopa/Entacapone Orion should be taken into consideration.
Upoštevati je treba možnost, da je bolnik vzel poleg zdravila Levodopa/Carbidopa/Entacapone Orion še druga zdravila.
No particular studies are reported on the pharmacokinetics of levodopa and carbidopa in patients with renal insufficiency, therefore Levodopa/Carbidopa/Entacapone Orion therapy should be administered cautiously to patients in severe renal impairment including those receiving dialysis therapy (see section 5.2).
Študije, v katerih bi posebej preučevali farmakokinetiko levodope in karbidope pri bolnikih z ledvično insuficienco niso bile izvedene, zato je potrebna previdnost pri dajanju zdravila Levodopa/Carbidopa/Entacapone Orion bolnikom s hudo prizadetostjo ledvic kot tudi tistim, ki se zdravijo z dializo (glejte poglavje 5.2).
- Dopamine Dysregulation Syndrome (DDS) is an addictive disorder resulting in excessive use of the product seen in some patients treated with carbidopa/levodopa.
- Sindrom motene regulacije dopamina (DDS - Dopamine Dysregulation Syndrome) je odvistnostna motnja, ki se odraža s pretirano uporabo zdravila, kar so opazili pri nekaterih bolnikih, zdravljenih s karbidopo/levodopo.
- If you are taking Levodopa/Carbidopa/Entacapone Orion 50 mg/12.5 mg/200 mg,
- Če jemljete zdravilo Levodopa/Carbidopa/Entacapone Orion 50 mg/12,5 mg/200 mg,
The safety of levodopa, carbidopa or entacapone in the infant is not known.
Varnost levodope, karbidope ali entakapona za dojene novorojence/otroke ni znana.
Do not stop taking Levodopa/Carbidopa/Entacapone Orion unless your doctor tells you to.
Ne prenehajte z jemanjem zdravila Levodopa/Carbidopa/Entacapone Orion razen po navodilih zdravnika.
Levodopa/Carbidopa/Entacapone Orion is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (DDC) inhibitor treatment.
Zdravilo Levodopa/Carbidopa/Entacapone Orion je indicirano pri odraslih bolnikih s Parkinsonovo boleznijo in motoričnimi fluktuacijami na koncu odmernega obdobja, ki jih zdravljenje z levodopo/zaviralci dopa-dekarboksilaze (DDK) ne stabilizira.
Dopamine dysregulation syndrome was included in five adverse drug reaction reports during this PSUR reporting period.
Sindrom motene regulacije dopamina je bil vključen v pet poročil o neželenih učinkih zdravil v obdobju tega PSUR-a. Kumulativno je bil vključen sindrom motene regulacije dopamina v 10 poročil.
- Levodopa/Carbidopa/Entacapone Orion therapy should be administered cautiously to patients with ischemic heart disease, severe cardiovascular or pulmonary disease, bronchial asthma, renal or endocrine disease, history of peptic ulcer disease or history of convulsions.
- Previdnost je potrebna tudi pri dajanju zdravila Levodopa/Carbidopa/Entacapone Orion bolnikom z ishemično boleznijo srca, s hudim kardiovaskularnim ali pljučnim obolenjem, bronhialno astmo, boleznijo ledvic ali žlez z notranjim izločanjem, kot tudi tistim, ki so kdaj v preteklosti imeli želodčno razjedo ali konvulzije.
Urticaria*
urtikarija*
- If you are taking Levodopa/Carbidopa/Entacapone Orion 175 mg/43.75 mg/200 mg tablets, do not take more than 8 tablets of this strength per day.
- Če jemljete zdravilo Levodopa/Carbidopa/Entacapone Orion 175 mg/43,75 mg/200 mg tablete, ne vzemite več kot 8 tablet dnevno.
- Levodopa/Carbidopa/Entacapone Orion may induce orthostatic hypotension.
- Zdravilo Levodopa/Carbidopa/Entacapone Orion lahko povzroči ortostatsko hipotenzijo.
Levodopa/Carbidopa/Entacapone Orion with food and drink
Zdravilo Levodopa/Carbidopa/Entacapone Orion skupaj s hrano in pijačo
- If you are taking Levodopa/Carbidopa/Entacapone Orion 200 mg/50 mg/200 mg, do not take more than 7 tablets of this strength per day.
- Če jemljete zdravilo Levodopa/Carbidopa/Entacapone Orion 200 mg/50 mg/200 mg tablete, ne vzemite več kot 7 tablet dnevno.
- Levodopa/carbidopa may cause false positive result when a dipstick is used to test for urinary ketone and this reaction is not altered by boiling the urine sample.
- Levodopa/karbidopa lahko povzročita lažno pozitivne rezultate, če se za testiranje ketonov uporablja testni trak.
Levodopa/Carbidopa/Entacapone Orion 50 mg/12.5 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 75 mg/18.75 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 100 mg/25 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 125 mg/31.25 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 150 mg/37.5 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 175 mg/43.75 mg/200 mg film-coated tablets Levodopa/Carbidopa/Entacapone Orion 200 mg/50 mg/200 mg film-coated tablets
Levodopa/Carbidopa/Entacapone Orion 50 mg/12,5 mg/200 mg filmsko obložene tablete Levodopa/Carbidopa/Entacapone Orion 75 mg/18,75 mg/200 mg filmsko obložene tablete Levodopa/Carbidopa/Entacapone Orion 100 mg/25 mg/200 mg filmsko obložene tablete Levodopa/Carbidopa/Entacapone Orion 125 mg/31,25 mg/200 mg filmsko obložene tablete Levodopa/Carbidopa/Entacapone Orion 150 mg/37,5 mg/200 mg filmsko obložene tablete Levodopa/Carbidopa/Entacapone Orion 175 mg/43,75 mg/200 mg filmsko obložene tablete Levodopa/Carbidopa/Entacapone Orion 200 mg/50 mg/200 mg filmsko obložene tablete
Management of acute overdose with Levodopa/Carbidopa/Entacapone Orion therapy is similar to acute overdose with levodopa.
Ukrepi pri akutnem prevelikem odmerjanju zdravila Levodopa/Carbidopa/Entacapone Orion so podobni kot pri akutnem prevelikem odmerjanju levodope.
Review of treatment is recommended if such symptoms develop.
Če pride do takih simptomov, je treba pregledati ustreznost zdravljenja.
Patients should be instructed to take only one Levodopa/Carbidopa/Entacapone Orion tablet per dose administration.
Bolnikom je treba razložiti, da naj ob vsakem odmerku vzamejo samo eno tableto zdravila Levodopa/Carbidopa/Entacapone Orion.
The daily dose should be preferably optimised using one of the seven available tablet strengths (50 mg/12.5 mg/200 mg, 75 mg/18.75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31.25 mg/200 mg, 150 mg/37.5 mg/200 mg, 175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg levodopa/carbidopa/entacapone).
Dnevni odmerek naj se po možnosti optimizira z uporabo tablet ustrezne jakosti - ene od sedmih, ki so na razpolago (50 mg/12,5 mg/200 mg, 75 mg/18,75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31,25 mg/200 mg, 150 mg/37,5 mg/200 mg, 175 mg/43,75 mg/200 mg ali 200 mg/50 mg/200 mg levodopa/karbidopa/entakapon).
A syndrome resembling the neuroleptic malignant syndrome including muscular rigidity, elevated body temperature, mental changes and increased serum creatine phosphokinase has been reported with the abrupt withdrawal of antiparkinsonian agents.
Ob nenadni ukinitvi antiparkinsonikov poročajo o pojavu sindroma podobnega malignemu nevroleptičnemu sindromu, ki vključuje otrplost mišic, povišano telesno temperaturo, duševne spremembe in povišane vrednosti serumske kreatin fosfokinaze.
Croscarmellose sodium Magnesium stearate Maize starch Mannitol (E421) Povidone K 30 (E1201)
Jedro tablete: natrijev karmelozat, premreženi (E468) magnezijev stearat koruzni škrob manitol (E421) povidon K 30 (E1201)
Initiation of Levodopa/Carbidopa/Entacapone Orion may be considered at corresponding doses to current treatment in some patients with Parkinson's disease and end-of-dose motor fluctuations, who are not stabilised on their current standard release levodopa/DDC inhibitor treatment.
O uvedbi zdravljenja z zdravilom Levodopa/Carbidopa/Entacapone Orion z odmerki, ki ustrezajo obstoječi terapiji, velja razmisliti pri nekaterih bolnikih s Parkinsonovo boleznijo in motoričnimi fluktuacijami na koncu odmernega obdobja, ki jih trenutno zdravljenje s standardnim sproščanjem levodope/zaviralci DDK ne stabilizira.
Colitis*, dysphagia
kolitis*, disfagija
5 How to store Levodopa/Carbidopa/Entacapone Orion Contents of the pack and other information
5 Shranjevanje zdravila Levodopa/Carbidopa/Entacapone Orion Vsebina pakiranja in dodatne informacije
Ten tablets of Levodopa/Carbidopa/Entacapone Orion 150 mg/37.5 mg/200 mg equals 375 mg of carbidopa a day.
Deset tablet zdravila Levodopa/Carbidopa/Entacapone Orion 150 mg/37,5 mg/200 mg je enako 375 mg karbidope na dan.
Serious hepatitis with mainly cholestatic features, rhabdomyolysis and neuroleptic malignant syndrome may occur with Levodopa/Carbidopa/Entacapone Orion although no cases have been identified from the clinical trial data.
Pri zdravilu Levodopa/Carbidopa/Entacapone Orion se lahko pojavi huda oblika hepatitisa s pretežno holestatskimi značilnostmi, rabdomioliza in nevroleptični maligni sindrom, čeprav v podatkih s kliničnega preskušanja niso opredelili nobenega primera.
Pack sizes of 75/18.75/200 mg, 125/31.25/200 mg, 175/43.75/200 mg and 200/50/200 mg: 10, 30, 100, 130 and 175 tablets.
Velikosti pakiranj za 75/18,75/200 mg, 125/31,25/200 mg, 175/43,75/200 mg in 200/50/200 mg: 10, 30, 100, 130 in 175 tablet.
What Levodopa/Carbidopa/Entacapone Orion is and what it is used for
Kaj je zdravilo Levodopa/Carbidopa/Entacapone Orion in za kaj ga uporabljamo
Levodopa/Carbidopa/Entacapone Orion may make it harder for you to digest iron.
Zaradi zdravila Levodopa/Carbidopa/Entacapone Orion boste morda težje presnavljali železo.
Impulse control disorders: Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments containing levodopa including Levodopa/Carbidopa/Entacapone Orion (see section 4.4).
Motnje pri obvladovanju impulzov: Pri bolnikih, ki se zdravijo z agonisti dopamina in/ali drugimi dopaminergičnimi zdravljenji, ki vsebujejo levodopo, vključno z zdravilom Levodopa/Carbidopa/Entacapone Orion, lahko pride do patološkega hazardiranja, povečanega libida, hiperseksualnosti, kompulzivnega zapravljanja ali nakupovanja, prenajedanja ali kompulzivnega prenajedanja (glejte poglavje 4.4).
Musculoskeletal and connective tissue disorders Very common:
Bolezni mišično-skeletnega sistema Zelo pogosti:
b. When initiating Levodopa/Carbidopa/Entacapone Orion therapy for patients currently treated with entacapone and levodopa/carbidopa in doses not equal to Levodopa/Carbidopa/Entacapone Orion tablets (50 mg/12.5 mg/200 mg or 75 mg/18.75 mg/200 mg or 100 mg/25 mg/200 mg or 125 mg/31.25 mg/200 mg or 150 mg/37.5 mg/200 mg or 175 mg/43.75 mg/200 mg or 200 mg/50 mg/200 mg), Levodopa/Carbidopa/Entacapone Orion dosing should be carefully titrated for optimal clinical response.
b. Ob uvajanju terapije z zdravilom Levodopa/Carbidopa/Entacapone Orion pri bolnikih, ki trenutno prejemajo entakapon in levodopo/karbidopo v odmerkih, ki se razlikujejo od tablet zdravila Levodopa/Carbidopa/Entacapone Orion (50 mg/12,5 mg/200 mg ali 75 mg/18,75 mg/200 mg ali 100 mg/25 mg/200 mg ali 125 mg/31,25 mg/200 mg ali 150 mg/37,5 mg/200 mg ali 175 mg/43,75 mg/200 mg ali 200 mg/50 mg/200 mg), je treba za dosego optimalnega kliničnega odgovora odmerjanje zdravila Levodopa/Carbidopa/Entacapone Orion skrbno titrirati.
Grounds for the variation to the terms of the Marketing Authorisations
Podlaga za spremembe pogojev dovoljenja (dovoljenj) za promet z zdravilom
Uncommon (may affect up to 1 in 100 people) - heart attack - bleeding in the gut - changes in the blood cell count which may result in bleeding, abnormal liver function tests - convulsions - feeling agitated - psychotic symptoms - colitis (inflammation of the colon) - discolourations other than urine (e.g. skin, nail, hair, sweat) - swallowing difficulties - inability to urinate
Občasni neželeni učinki (lahko se pojavijo pri največ 1 od 100 bolnikov): - srčni napad - krvavitve v črevesju - spremembe v številu krvničk, kar lahko povzroči krvavitve, nenormalne rezultate jetrnih testov - konvulzije - občutek vznemirjenosti - psihotični simptomi - kolitis (vnetje debelega črevesa) - obarvanja, razen urina (npr. kože, nohtov, las, znoja)
If therapy has to be stopped temporarily, Levodopa/Carbidopa/Entacapone Orion may be restarted as soon as oral medicinal products can be taken at the same daily dose as before.
Če je treba terapijo začasno prekiniti, se lahko zdravljenje z zdravilom Levodopa/Carbidopa/Entacapone Orion nadaljuje z enakim režimom odmerjanja kot pred prekinitvijo takoj, ko je možna peroralna aplikacija.
If you take more Levodopa/Carbidopa/Entacapone Orion than you should
Če ste vzeli večji odmerek zdravila Levodopa/Carbidopa/Entacapone Orion, kot bi smeli
- The active substances of Levodopa/Carbidopa/Entacapone Orion are levodopa, carbidopa and entacapone.
- Učinkovine zdravila Levodopa/Carbidopa/Entacapone Orion so levodopa, karbidopa in entakapon.
Talk to your doctor or pharmacist before taking Levodopa/Carbidopa/Entacapone Orion if you have or have ever had: - a heart attack or any other diseases of the heart including cardiac arrhythmias, or of the blood vessels - asthma or any other disease of the lungs
Pred začetkom jemanja zdravila Levodopa/Carbidopa/Entacapone Orion se posvetujte z zdravnikom ali farmacevtom: - srčni napad ali katero koli drugo bolezen srca, vključno z srčnimi aritmijami, ali bolezni ožilja; - astmo ali druge pljučne bolezni; - težave z jetri, saj bo morda treba odmerek prilagoditi;